10 ADHD Clinical Trials in Tucson, AZ (2026)

Q: How do I join a clinical trial in Tucson?

Browse available studies, click one that interests you, and complete the free eligibility form. A study coordinator at the Tucson research site will contact you.

Recruiting ADHD Studies in Tucson

NCT05614739Recruiting

FORAGER-1: A Study of LOXO-435 (LY3866288) in Participants With Cancer With a Change in a Gene Called FGFR3

The main purpose of this study is to learn more about the safety, side effects, and effectiveness of LOXO-435 by itself or when it is combined with other standard medicines that treat cancer. LOXO-435...

Tucson, AZPHASE1677 participantsEli Lilly and Company

View Study Details

NCT06510374Recruiting

Trial of Nadofaragene Firadenovec vs. Observation in Participants With Intermediate Risk Non-Muscle Invasive Bladder Cancer

A phase 3b, Randomized, Controlled Trial of Nadofaragene Firadenovec vs. Observation in Participants with Intermediate Risk Non-Muscle Invasive Bladder Cancer (IR NMIBC)...

Tucson, AZPHASE3454 participantsFerring Pharmaceuticals

View Study Details

NCT04752722Recruiting

LEGEND Study: EG-70 in NMIBC Patients BCG-Unresponsive and High-Risk NMIBC Incompletely Treated With BCG or BCG-Naïve

This study will evaluate the safety and efficacy of intravesical administration of EG-70 in the bladder and its effect on bladder tumors in patients with NMIBC. This study study consists of two phase...

Tucson, AZPHASE1350 participantsenGene, Inc.

View Study Details

NCT06567743Recruiting

Phase 2 Study to Evaluate Safety and Efficacy of Cretostimogene Grenadenorepvec in High-Risk NMIBC

This is a Phase 2, Multi-Arm, Multi-Cohort, Open-Label Study to Evaluate the Safety and Efficacy of Cretostimogene Grenadenorepvec in Participants with High-Risk Non-Muscle-Invasive Bladder Cancer....

Tucson, AZPHASE2325 participantsCG Oncology, Inc.

View Study Details

NCT06545955Recruiting

A Trial to Evaluate Intravesical Nadofaragene Firadenovec Alone or in Combination With Chemotherapy or Immunotherapy in Participants With High-grade BCG Unresponsive Non-muscle Invasive Bladder Cancer

The pivotal phase 3 trial (rAd-IFN-CS 003) evaluating the efficacy of nadofaragene firadenovec showed that 55 (53.4%) of 103 subjects with CIS ± high-grade Ta/T1 achieved a complete response (CR) at 3...

Tucson, AZPHASE3250 participantsFerring Pharmaceuticals

View Study Details

NCT06770582Recruiting

Testing the Addition of the Immunotherapy Drug, Pembrolizumab, to Radiation Therapy Compared to the Usual Chemotherapy Treatment During Radiation Therapy for Bladder Cancer, PARRC Trial

This phase II trial compares the use of pembrolizumab and radiation therapy to chemotherapy with cisplatin, gemcitabine, 5-fluorouracil or mitomycin-C and radiation therapy for the treatment of non-mu...

Tucson, AZPHASE2160 participantsNational Cancer Institute (NCI)

View Study Details

NCT05521698Recruiting

A Randomized Trial of Bicalutamide in Non-Muscle Invasive Bladder Cancer

This phase I trial evaluates the effects of bicalutamide, compared to no study drug (NSD), on epidermal growth factor receptor (EGFR) protein expression in patients with non-muscle invasive bladder ca...

Tucson, AZPHASE180 participantsUniversity of Wisconsin, Madison

View Study Details

NCT05710848Recruiting

A Study of STM-416 Administered to Patients Undergoing TURBT for Recurrent Bladder Cancer

This is a first-in-human (FIH), Phase 1/2a, multi center, open-label, single treatment, dose escalation and expansion study designed to determine the safety and tolerability of STM-416 in patients wit...

Tucson, AZPHASE175 participantsSURGE Therapeutics

View Study Details

NCT06394830Recruiting

Safety, Efficacy, and Frequency of Administration of VNX001 in the Treatment of Interstitial Cystitis / Bladder Pain Syndrome (IC/BPS)

This is an open-label study that will enroll participants with Interstitial Cystitis / Bladder Pain Syndrome (IC/BPS). The study will assess PRN (as needed) dosing of up to 6 intravesical (via cathet...

Tucson, AZPHASE250 participantsVaneltix Pharma, Inc.

View Study Details

NCT06682949Recruiting

Daily Routines, Executive Functioning & ADHD

The goal of this clinical trial is to learn adjusting daily or nightly routines improves executive functioning in youth with ADHD. It will also learn about the acceptability of the intervention. The ...

Tucson, AZNA25 participantsCori Manning

View Study Details

About ADHD Clinical Trials in Tucson

Attention deficit hyperactivity disorder (ADHD) is a neurodevelopmental disorder characterized by inattention, hyperactivity, and impulsivity that interferes with functioning. It affects both children and adults. Treatment includes behavioral therapy, stimulant and non-stimulant medications, and educational support.

There are currently 10 adhd clinical trials recruiting participants in Tucson, AZ. These studies are seeking a combined 2,446 participants. Research is being sponsored by Eli Lilly and Company, Ferring Pharmaceuticals, enGene, Inc. and 6 other organizations. Clinical trial participation is free and participants receive study-related medical care at no cost.

ADHD Clinical Trials in Tucson — FAQ

Are there adhd clinical trials in Tucson?

Yes, there are 10 adhd clinical trials currently recruiting in Tucson, AZ. Browse the studies on this page to find one that fits.

How do I join a clinical trial in Tucson?

Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Tucson research site will contact you about next steps.

Are clinical trials in Tucson free?

Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Tucson studies also compensate for your time and travel.

What adhd treatments are being tested?

The 10 active trials in Tucson are testing new therapies including novel drugs, biologics, and treatment approaches for adhd.

Data updated October 12, 2026 from ClinicalTrials.gov